

**Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and Waiver under 18 U.S.C. §208(b)(3)**

Ronald Portman, M.D.

Committee: Cardiovascular and Renal Drugs Advisory
Committee

Meeting Date: April 26, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to agenda item concerning the discussion of the Agency's draft recommendations for re-labeling of anti-hypertensive drugs for outcome claims, as a follow-up to the committee's meeting on June 15, 2005, where the committee discussed class labeling of antihypertensive drugs based on the proximity of their data to outcome trials, I am eligible to receive a waiver under 18 U.S.C. §208(b)(3).

Type of Interest	Nature	Magnitude
Employer's Related Studies	Four Affected Firms	Less than \$100,000 per year from each firm.
Consulting	Two Affected Firms	Less than \$10,001 per year from each firm.
Consulting	Two Affected Firms	Between \$10,001 to \$50,000 per year.
Advisory Board	Affected Firm	Less than \$10,001 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of the interest, the waiver is not valid.

_____/S/_____
Signature of SGE

_____/3/21/06_____
Date